ASH Annual Meeting

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

The MajesTEC-3 trial showed that teclistamab combined with subcutaneous daratumumab improved overall survival vs standard daratumumab-based regimens in relapsed/refractory multiple myeloma.

Pirtobrutinib shows significant improvement in progression-free survival for untreated CLL/SLL, potentially setting a new standard of care.

Sonrotoclax shows promising efficacy and tolerability in treating relapsed mantle cell lymphoma, with ongoing trials to confirm its potential.

A new triplet therapy combining tagraxofusp, azacitidine, and venetoclax shows promising response rates and transplant potential for BPDCN patients.

The KOMET-007 trial reveals promising safety and efficacy of ziftomenib combined with venetoclax and azacitidine for relapsed/refractory AML patients.

Circulating tumor DNA (ctDNA) emerges as a crucial prognostic tool for lymphoma, enhancing event-free survival predictions and treatment response insights.

The MagnetisMM-30 trial reveals promising early responses and manageable safety for elranatamab and iberdomide in relapsed multiple myeloma patients.

A novel treatment regimen for high-risk mantle cell lymphoma shows impressive response rates and minimal residual disease in early trial results.

A recent study reveals that Black patients with acute myeloid leukemia face significantly poorer survival rates compared to White patients, highlighting racial disparities in treatment outcomes.

Cilta-cel shows promising long-term survival rates in relapsed/refractory multiple myeloma, suggesting potential for a cure in standard-risk patients.

A new combination therapy shows promising results in achieving durable remission for patients with NPM1-mutated acute myeloid leukemia.

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates.

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient outcomes.

NXC-201 CAR T-cell therapy shows promising results in treating relapsed AL amyloidosis, achieving deep responses and rapid normalization of disease markers.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

Long-term follow-up of the TRANSFORM study reveals liso-cel's impressive efficacy and safety in treating relapsed large B-cell lymphoma.

The SAVE regimen demonstrates promising efficacy in newly diagnosed AML, achieving high response rates but raises concerns about myelosuppression.

A promising trial reveals high response rates and survival outcomes for decitabine/cedazuridine and venetoclax in high-risk hematologic malignancies.

A phase 2 study reveals promising results for zanubrutinib combined with R-CHOP in treating untreated diffuse large B-cell lymphoma patients.

GLPG5101 shows promising efficacy and safety in treating relapsed/refractory non-Hodgkin lymphoma, achieving high response rates and rapid manufacturing.

Linvoseltamab shows promising efficacy and safety as a monotherapy for newly diagnosed multiple myeloma, offering a simpler treatment alternative.

Cevostamab shows promising efficacy and manageable safety in treating relapsed/refractory multiple myeloma, offering a convenient subcutaneous administration option.

New research highlights measurable residual disease (MRD) as a key predictor of survival in acute myeloid leukemia, potentially transforming treatment strategies.

A targeted therapy-first approach shows promise in reducing chemotherapy needs for newly diagnosed large B-cell lymphoma patients, maintaining high response rates.

Pirtobrutinib demonstrates an impressive 81.6% response rate in CLL/SLL patients previously treated with BTK inhibitors, showcasing its efficacy and safety.

Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib shows superior overall response rates and promising progression-free survival compared to ibrutinib in treating chronic lymphocytic leukemia.

Epcoritamab combined with rituximab and lenalidomide shows remarkable efficacy in treating relapsed follicular lymphoma, setting a new standard of care.